Cat. #152156
Anti-Cytochrome P450 4A11 [M25-P2A10]
Cat. #: 152156
Sub-type: Primary antibody
Unit size: 100 ug
Target: Cytochrome P450, family 4, subfamily A, polypeptide 11 (CYP4A11)
Class: Monoclonal
Application: ELISA ; IHC ; WB
Reactivity: Drosophila ; Human ; Mouse ; Rat ; Xenopus laevis
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Ayham Alnabulsi
Institute: Vertebrate Antibodies Limited
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-Cytochrome P450 4A11 [M25-P2A10]
- Research fields: Cancer;Cell signaling and signal transduction;Metabolism;Tissue-specific biology
- Clone: M25-P2A10
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Drosophila ; Human ; Mouse ; Rat ; Xenopus laevis
- Host: Mouse
- Application: ELISA ; IHC ; WB
- Description: CYP4A11 is upregulated in primary and metaststic CRC tumours compared to normal colon mucosa.
- Immunogen: Peptide Sequence KNGIHLRLR (amino acids 499 507)
- Isotype: IgG1 kappa
- Myeloma used: P3X63Ag8.653
- Recommended controls: ELISA- Peptide immunogen; Western Blot- Human liver microsomes; IHC-Human liver
Target Details
- Target: Cytochrome P450, family 4, subfamily A, polypeptide 11 (CYP4A11)
- Tissue cell line specificity: ELISA- Peptide immunogen; Western Blot- Human liver microsomes; IHC-Human liver
- Target background: CYP4A11 is upregulated in primary and metaststic CRC tumours compared to normal colon mucosa.
Applications
- Application: ELISA ; IHC ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Alnabulsi et al. 2017. Br J Cancer. :. PMID: 28557975.
- The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance.
- Alnabulsi et al. 2016. Characterisation of Arachidonic Acid Metabolising Enzymes in Colorectal Cancer J Pathol. 240 Suppl 1:S1-S48. PMID: 27747872
- Nottingham Pathology 2016. 9th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 28 June - 1 July 2016.
